Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NSCLC × cemiplimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 20 Squamous Cell Carcinoma of Head and Neck 7 Lung Neoplasms 7 Neoplasms 6 Melanoma 6 Carcinoma, Squamous Cell 5 Skin Neoplasms 4 Carcinoma, Renal Cell 4 Urinary Bladder Neoplasms 3 Head and Neck Neoplasms 3 Colonic Neoplasms 3 Carcinoma 3 Breast Neoplasms 3 Adenocarcinoma 3 Rectal Neoplasms 2 Pancreatic Neoplasms 2 Oropharyngeal Neoplasms 2 Neoplasm Metastasis 2 Mesothelioma, Malignant 2 Carcinoma, Merkel Cell 2 Carcinoma, Hepatocellular 2 Carcinoma, Basal Cell 2 Adrenocortical Carcinoma 2 Vulvar Neoplasms 1 Vaccinia 1 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1 Thoracic Neoplasms 1 Solid Tumors 1 Small Cell Lung Carcinoma 1

Interventions

osimertinib 5 Carboplatin 5 Drug Therapy 4 tislelizumab 3 anlotinib 3 aflutinib 3 Radiotherapy 3 Pemetrexed 3 toripalimab 2 pembrolizumab 2 apatinib 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Radiosurgery 2 Paclitaxel 2 HM781-36B 2 Cisplatin 2 Chemotherapy, Adjuvant 2 Chemoradiotherapy 2 trilaciclib 1 surufatinib 1 sintilimab 1 rezivertinib 1 lenvatinib 1 icotinib 1 envafolimab 1 dacomitinib 1 cemiplimab 1 camrelizumab 1 brigatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06865339 2025-09-10

TRIPL

Albert Einstein College of Medicine

Phase 2 Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡